Successful treatment of lichen amyloidosis coexisting with atopic dermatitis by dupilumab: Four case reports

Abstract

BACKGROUND Lichen amyloidosis (LA) is a chronic, severely pruritic skin disease, which is the most common form of primary cutaneous amyloidosis. The treatment of LA has been considered to be difficult. LA may be associated with atopic dermatitis (AD), and in this setting, the treatment options may be more limited. Herein, we report four cases of LA associated with AD successfully treated by dupilumab. CASE SUMMARY In this article, we describe four cases of patients who presented with recurrent skin rash accompanied by severe generalized intractable pruritus, diagnosed with refractory LA coexisting with chronic AD. Previous treatments had not produced any apparent improvement. Thus, we administered dupilumab injection subcutaneously at a dose of 600 mg for the first time and 300 mg every 2 wk thereafter. Their lesions all markedly improved. CONCLUSION Dupilumab may be a new useful treatment for LA coexisting with AD.

Lichen Amyloidosis in an Atopic Patient Treated with Dupilumab: A New Therapeutic Option

“…Dupilumab has also received Food and Drug Administration (FDA) approval for use in PN, and there are several off-label studies concerning its application in additional dermatological disorders [33]. Concerning LA, there are only 7 other cases of LA and AD effectively treated with Dupilumab in the literature [21][22][23][24] and one case of isolated generalized LA [7].…”

Lichen Amyloidosis in an Atopic Patient Treated with Dupilumab: A New Therapeutic Option

“…Dupilumab has also received Food and Drug Administration (FDA) approval for use in PN, and there are several off-label studies concerning its application in additional dermatological disorders [33]. Concerning LA, there are only seven other cases of LA and AD effectively treated with Dupilumab in the literature [21][22][23][24] and one case of isolated generalized LA [7]. In these cases, Dupilumab led to the total disappearance of pruritus after the first 3 months of treatment and to the remission of the lesions between the first 3 and 6 months of treatment.…”

“…In addition, satisfactory results have also been reported using amitriptyline and transcutaneous nerve stimulation [3]. Finally, there are a small number of case reports in the literature in which biological drugs such as Upadacitinib [19], Baricitinib [20], and Dupilumab [7,[21][22][23] have been used.…”